Efficacy and safety of adjuvant targeted immunotherapy for hepatocellular carcinoma with high recurrence risks after hepatectomy

doi:10.4240/wjgs.119272

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 6

This Article

(21)

(32)

(0)

(17)

(280)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Surg. Jun 27, 2026; 18(6): 119272
Published online Jun 27, 2026. doi: 10.4240/wjgs.119272

Table 3 Recurrence-free and overall survival rates before and after propensity score matching

	PSM before			PSM after
	ATG (n = 88)	SG (n = 284)	P value	ATG (n = 88)	SG (n = 88)	P value
Median recurrence-free survival (months)	26.0	16.0	0.038	26.0	14.0	0.028
1-year recurrence-free survival rate (%)	79.5	63.7	0.006	79.5	62.3	0.013
Number of deaths (n)	3	12		3	6
Median overall survival, months			1.000			1.000
1-year overall survival rate (%)	100.0	100.0	1.000	100.0	100.0	1.000
Overall survival rate (%)	96.6	95.8	0.976	96.6	93.3	0.494

PSM: Propensity score matching; ATG: Adjuvant therapy group; SG: Surgery-alone group.

Full Size Table

Citation: Li QS, Hu AY, Chen SJ, Yu GJ, Fan Y, Chen YG, Tian S, Peng CJ, Han M. Efficacy and safety of adjuvant targeted immunotherapy for hepatocellular carcinoma with high recurrence risks after hepatectomy. World J Gastrointest Surg 2026; 18(6): 119272
URL: https://www.wjgnet.com/1948-9366/full/v18/i6/119272.htm
DOI: https://dx.doi.org/10.4240/wjgs.119272

Li QS, Hu AY, Chen SJ, Yu GJ, Fan Y, Chen YG, Tian S, Peng CJ, Han M. Efficacy and safety of adjuvant targeted immunotherapy for hepatocellular carcinoma with high recurrence risks after hepatectomy. World J Gastrointest Surg 2026; 18(6): 119272 [DOI: 10.4240/wjgs.119272]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.